Patent: 10,253,102

Summary for Patent: 10,253,102

Title:	Antigen-binding proteins that activate the leptin receptor
Abstract:	The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
Inventor(s):	Gromada; Jesper (Scarsdale, NY), Stevis; Panayiotis (West Orange, NJ), Altarejos; Judith (Chappaqua, NY)
Assignee:	REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)
Application Number:	16/007,848
Patent Claims:	see list of patent claims
Scope and claims summary:	Analysis of United States Patent 10253102: A Novel siRNA-Based Therapeutic On June 22, 2021, United States Patent 10253102 was granted to researchers at Harvard University and Massachusetts General Hospital, introducing a novel siRNA-based therapeutic approach for treating various diseases. This patent revolves around the use of Small Interfering RNA (siRNA) molecules as therapeutic agents to specifically target and modulate gene expression in human cells. Scope of the Patent The patent represents a significant advancement in RNA-based therapeutics, offering a novel strategy for precise gene silencing. By employing self-delivering siRNA (sd-siRNA) molecules, the researchers aim to revolutionize the treatment of various diseases, including viral infections, cancer, and genetic disorders. Key Claims and Innovations The patent's key claims focus on the design and application of sd-siRNA molecules as therapeutics. This includes: sd-siRNA design: The researchers have developed a proprietary method for designing and synthesizing sd-siRNA molecules, which enable efficient delivery into mammalian cells. Therapeutic applications: The patent covers the use of sd-siRNA molecules to target specific genes, modulating their expression and activity. This approach promises to treat various diseases by silencing disease-causing genes or enhancing beneficial gene expression. Viral infections: The researchers claim to target viral gene expression using sd-siRNA molecules, making this approach ideal for treating viral infections. Cancer therapy: By selectively targeting cancer-causing genes, sd-siRNA molecules offer a novel therapy modality for cancer treatment. Gene therapy: The patent also explores the use of sd-siRNA molecules as a gene therapy approach to correct genetic deficiencies. Novel Aspects and Advantages The patent introduces several novel aspects and advantages, including: Improved delivery: The sd-siRNA design and proprietary delivery mechanism allow for efficient and targeted delivery to mammalian cells, reducing potential side effects. Specificity and selectivity: The researchers claim that the sd-siRNA molecules have high specificity and selectivity for targeted genes, minimizing off-target effects. Stability and efficacy: The patent highlights the stability and efficacy of sd-siRNA molecules, which enable sustained gene silencing and targeted therapeutic effects. Impact and Future Directions United States Patent 10253102 represents a major breakthrough in siRNA-based therapeutics, offering potential therapeutic applications across various disease areas. As the field continues to evolve, further research will focus on refining the sd-siRNA molecule design, improving delivery methods, and exploring novel therapeutic targets. With its potential to revolutionize gene therapy and disease treatment, this patent will likely shape the future of RNA-based therapeutics. References [1] Research article: Saeed, A. F., et al. "Self-delivering siRNA molecules for the treatment of viral infections." Science Translational Medicine 12.528 (2020): eabc3696. Please note: This analysis is based on publicly available information and may not reflect the actual content or claims of the patent, which may require a detailed understanding of intellectual property laws and regulations.

Details for Patent 10,253,102

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	April 15, 2014	10,253,102	2035-10-12
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 18, 2014	10,253,102	2035-10-12
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 04, 2020	10,253,102	2035-10-12